AUTHORS
Michael J. Thirman, Gabriel Mannis I, MD2, Cristina Papayannidis, MD, PhD3, Michael M.W. Kühn, MD4, Hartmut Döhner, MD5, Andre C. Schuh Sr, BSc, MD, FRCPC6, Ashish Bajel, MD7, Li Yu, PhD8, Lincy Thomas9, Ghayas C. Issa, MD10, Carolyn S. Grove, MBBS, PhD, FRACP, FRCPA11, John G. Harpel, MD, PhD12, Ioannis Mantzaris, MD, MS13, Pau Montesinos, MD14, Elie Traer, MD, PhD15
AFFILIATIONS
1 University of Chicago Medicine, Chicago, Illinois, United States
2 Stanford University School of Medicine, and Stanford Cancer Institute, Stanford, California, United States
3 IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, Bologna, Italy
4 University Medical Center, Johannes Gutenberg-University, Mainz, Germany
5 Ulm University Hospital, Ulm, Germany
6 Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
7 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia
8 Syndax Pharmaceuticals, Inc., New York, New York, United States
9 Syndax Pharmaceuticals, Inc., New York, New York, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 Sir Charles Gairdner Hospital, PathWest, and The University of Western Australia, Nedlands, WA, Australia
12 ICON plc, Blue Bell, Pennsylvania, United States
13 Montefiore Einstein Comprehensive Cancer Center, Bronx, New York, United States
14 Hospital Universitari i Politècnic La Fe, Valencia, Spain
15 Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon, United States
ABSTRACT
Background: Red blood cell (RBC) and platelet transfusion dependence is common in patients with acute leukemia and can also occur as a consequence of treatment. Transfusion dependence in patients with acute myeloid leukemia (AML) is associated with reduced quality of life and inferior treatment outcomes. Revumenib, a first-in-class, oral, potent, and selective inhibitor of the menin-KMT2A interaction, is used for the treatment of relapsed/refractory (R/R) AML harboring an NPM1 mutation (NPM1m) or R/R acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older. In the AUGMENT-101 trial (NCT04065399), revumenib monotherapy demonstrated clinically meaningful responses in a heavily pretreated, older population with R/R NPM1m AML. The current analysis characterized the impact of revumenib on transfusion dependence in patients with R/R NPM1m AML.
Methods: AUGMENT-101 is an ongoing, phase 1/2, open-label, dose-escalation and -expansion study of revumenib in patients with R/R acute leukemia. Patients who received the recommended phase 2 dose (RP2D) of revumenib were included in this analysis (160 mg [95 mg/m2 if <40 kg] with a strong CYP3A4 inhibitor or 270 mg [160 mg/m2 if <40 kg] without a strong CYP3A4 inhibitor in 28-day cycles). Transfusion independence was defined as any transfusion-free period (both RBC and platelet transfusions) lasting for ≥56 consecutive days. The baseline period was defined as 56 days prior to the first dose of revumenib. The post-baseline period was defined from first dose of revumenib to death, start of new anti-leukemic therapy including hematopoietic stem cell transplant and conditioning regimen, or data cutoff, whichever was earlier. The efficacy population comprised patients who received ≥1 dose of revumenib at RP2D with ≥5% baseline morphological blasts. This analysis was descriptive and not powered to allow statistical comparisons.
Results: Among the 91 patients with R/R NPM1m AML in the safety population of AUGMENT-101, 65 (71%) were baseline transfusion dependent and 26 (29%) were baseline transfusion independent. Median age was 63 years in both subgroups. Patients had received a median of 2 prior lines of therapy, and the majority had prior venetoclax exposure (transfusion-dependent subgroup: 50/65 [77%]; transfusion-independent subgroup: 16/26 [62%]). At data cutoff (19Feb2026), median (range) duration of follow-up was 3.8 (0.2–58.2) mo in the transfusion-dependent subgroup and 6.4 (0.1–45.1) mo in the transfusion-independent subgroup.
At baseline in the efficacy-evaluable population, 63/89 (71%) patients were dependent on RBC and/or platelet transfusions. After revumenib treatment, 13/63 (21%) patients became transfusion independent. At baseline, 26/89 (29%) patients were independent of RBC and platelet transfusions. After revumenib treatment, 17/26 (65%) patients remained transfusion independent.
Grade ≥3 treatment-emergent adverse events of thrombocytopenia/platelet count decreased occurred in 17/65 (26%) and 10/26 (39%) patients who were baseline transfusion dependent and transfusion independent, respectively. Grade ≥3 anemia occurred in 17/65 (26%) and 6/26 (23%) patients, respectively.
Conclusions: In AUGMENT-101, most patients were dependent on RBC and/or platelet transfusions at baseline. After treatment with revumenib monotherapy, 21% of patients who were transfusion dependent became transfusion independent and 65% of patients who were transfusion independent remained independent. The reduction in transfusion burden observed following treatment with revumenib monotherapy represents an additional patient-relevant outcome in adults with R/R NPM1m AML.
DISCLOSURES
Michael J. Thirman: AbbVie - Honoraria; AbbVie, Nurix, Syndax, Merck - Research Funding; AstraZeneca, Genentech, AbbVie, Adaptive, Syndax - Consultancy (Includes expert testimony)